# AIMEDBIO: Phase 1 study started recruiting, 86 planned (Solid Tumours)

**Score:** 60/100

| Field | Value |
|---|---|
| Sponsor | AIMEDBIO |
| Sponsor type | Non-US government |
| Study | A Study to Test How Well Different Doses of BI 4060107 Are Tolerated by People With Advanced Cancer (Solid Tumours) |
| NCT ID | NCT07827144 |
| Phase | Phase 1 |
| Status | recruiting |
| Conditions | Solid Tumours |
| Intervention types | biological |
| Target enrollment | 86 |
| Site countries | United States, Australia, France, Japan, South Korea |
| Posted | 2026-09-18 |
| Planned start | 2026-10-09 |
| Event | Started recruiting |
| Event date | 2026-10-09 |
| Last update posted | 2026-10-28 |

## Why this score
- Posted in the last two weeks.
- Just started recruiting: sites, recruitment and supply are active.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07827144). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.